RApid Diagnosis And Risk stratification of Acute Coronary Syndrome with novel biochip array

RApid Diagnosis And Risk stratification of Acute Coronary Syndrome with novel biochip array: an observational cohort study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN60873148

Enrollment

650

Registered

2011-02-09

Start date

2009-10-27

Completion date

Unknown

Last updated

2017-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome Circulatory System Other acute ischaemic heart diseases

Interventions

Patients will have blood sampled at admission then subsequently at time intervals 1, 2, 3, 6, 12 and 24 hours after admission. Blood will be spun and serum/plasma aliquoted then frozen at -80 degrees

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Consecutive male and female patients over 18 years of age with a clinical diagnosis of possible acute coronary syndrome.

Exclusion criteria

Exclusion criteria: 1. Unable to provide informed consent 2. Terminal malignancy 3. Patient received anticogulant treatment or fibrinolysis prior to enrolment

Design outcomes

Primary

Measure	Time frame
1. Sensitivity and specificity of investigational biomarkers when compared to troponin T at two prespecified time points after symptom onset: 4 hours, 6 hours 2. Major adverse cardiac events (MACE) defined as in hospital reinfarction (defined as further clinical signs and/or symptoms and greater than or equal to 20% increase in Troponin value 6 - 9 hours after the event), stroke, revascularisation, further admission with ACS heart failure hospitalisation, death	—

Measure

Time frame

1. Sensitivity and specificity of investigational biomarkers when compared to troponin T at two prespecified time points after symptom onset: 4 hours, 6 hours 2. Major adverse cardiac events (MACE) defined as in hospital reinfarction (defined as further clinical signs and/or symptoms and greater than or equal to 20% increase in Troponin value 6 - 9 hours after the event), stroke, revascularisation, further admission with ACS heart failure hospitalisation, death

—

Secondary

Measure	Time frame
1. Bleeding complications (assessed according to the TIMI bleeding classification) 2. In hospital revascularistion. Within this subset presenting coronary anatomy and revascularisation type will be assessed 3. Length of hospital stay	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026